Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center

Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center

IntroductionMedullary thyroid carcinoma (MTC) is a rare cancer that accounts for 5% of thyroid cancers. Serum calcitonin is a good biomarker for MTC, which is used for diagnosis, prognosis, and monitoring of recurrence. Calcitonin-negative MTC (CNMTC) is rare but confounds diagnostic and prognostic...

Full description

Bibliographic Details
Main Authors:	Sun Jung Kim, Hyeok Jun Yun, Su-Jin Shin, Yong Sang Lee, Hang-Seok Chang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Endocrinology
Subjects:	thyroid cancer calcitonin case series medullary thyroid carcinoma (MTC) calcitonin-negative medullary thyroid carcinoma.
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2021.747704/full

Similar Items

Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma
by: Wenliang Yue, et al.
Published: (2022-11-01)

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass
by: LI Rui, LIU Zhuoran, YAN Jiqi
Published: (2022-06-01)

Calcitonin receptor expression in medullary thyroid carcinoma
by: Virginia Cappagli, et al.
Published: (2017-09-01)

False positive results using calcitonin as a screening method for medullary thyroid carcinoma
by: Rafael Loch Batista, et al.
Published: (2013-01-01)

Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
by: Claudio Gambardella, et al.
Published: (2019-05-01)

Cytodiagnosis of medullary carcinoma thyroid- role of FNAC and serum calcitonin- A case report
by: Majed B Momin, et al.
Published: (2018-01-01)

Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review
by: Li Chen, et al.
Published: (2020-10-01)

Diagnosis and treatment of medullary thyroid carcinoma-an update
by: CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben
Published: (2022-06-01)

Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis
by: Irfan Vardarli, et al.
Published: (2021-04-01)

Breast metastasis from medullary thyroid carcinoma: a report of a case
by: Yoko Omi, et al.
Published: (2021-08-01)

Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence
by: Qiaodan Zhu, et al.
Published: (2021-04-01)

Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines
by: Daqi Zhang, et al.
Published: (2022-07-01)

Critically evaluated key points on hereditary medullary thyroid carcinoma
by: Daqi Zhang, et al.
Published: (2024-06-01)

Calcitonin-negative primary neuroendocrine tumor of the thyroid (nonmedullary) in a dog
by: E.A. Soler Arias, et al.
Published: (2016-11-01)

Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer
by: Il Youb Jeong, et al.
Published: (2024-08-01)

Nephrotic Syndrome as a Complication of Systemic Calcitonin Amyloidosis From Long-Standing Metastatic Medullary Thyroid Cancer
by: Samantha M. Siskind, MD, et al.
Published: (2024-11-01)

To screen or not to screen for medullary thyroid cancer? This is (yet) the question. An illustrative case.
by: Rosaria Ruggeri, et al.
Published: (2018-12-01)

The role of procalcitonin in the follow-up of medullary thyroid cancer
by: Jacopo Manso, et al.
Published: (2023-01-01)

Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin
by: Bo Wang, et al.
Published: (2024-10-01)

Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows
by: Simona Censi, et al.
Published: (2021-10-01)

Survival in medullary thyroid carcinoma patients who fail to achieve a biochemical cure: implications of postoperative 1-month calcitonin levels and targeted therapy
by: Yixuan Song, et al.
Published: (2024-09-01)

Determinants of circulating calcitonin value: analysis of thyroid features, demographic data, anthropometric characteristics, comorbidities, medications, and smoking habits in a population with histological full exclusion of medullary thyroid carcinoma
by: Pierpaolo Trimboli, et al.
Published: (2024-01-01)

Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma
by: Fengli Guo, et al.
Published: (2024-05-01)

Measuring discrepancies between simple medullary and synchronous medullary/papillary thyroid carcinomas: a comparative cross-sectional study
by: Daqi Zhang, et al.
Published: (2024-01-01)

The value of routine measurement of serum calcitonin on insufficient, indeterminate, and suspicious thyroid nodule cytology
by: Muhammed Erkam Sencar, et al.
Published: (2022-02-01)

Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
by: Pierpaolo Trimboli, et al.
Published: (2018-06-01)

Simultaneous occurrence of medullary and papillary thyroid microcarcinomas: a case series and review of the literature
by: Adnan Zaina, et al.
Published: (2013-01-01)

Clinicopathological characteristics and prognostic analysis of medullary thyroid carcinoma in children and adolescents
by: LIU Wei , WANG Xiaojiang , ZHANG Jing , ZHU Weifeng , PENG Fengying , WANG Jianchao , XIAO Weijin , HU Dan
Published: (2021-11-01)

Metastatic medullary thyroid carcinoma: A case report
by: Mitra Niafar, et al.
Published: (2011-01-01)

Changes of biochemical factors and the effect on recurrence of medullary thyroid carcinoma after surgery
by: Fengli Guo, et al.
Published: (2024-04-01)

Calcitonin‐secreting pancreatic neuroendocrine tumor in a patient with elevated thyroid fine‐needle aspirate calcitonin washout: A case report and review of the literature
by: Darryl Mason, et al.
Published: (2022-01-01)

Calcitonin testing in patients with thyroid nodules for screening medullary thyroid carcinoma: a “gray zone”
by: N. V. Severskaya, et al.
Published: (2022-08-01)

Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma
by: Hyunju Park, et al.
Published: (2021-10-01)

Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study
by: Zan Jiao, et al.
Published: (2022-12-01)

Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update
by: Liu S, et al.
Published: (2024-04-01)

Early calcitonin levels in medullary thyroid carcinoma: Prognostic role in patients without distant metastases at diagnosis
by: Clotilde Sparano, et al.
Published: (2023-02-01)

A rare case of medullary carcinoma
by: O.Z. Lishchuk, et al.
Published: (2023-10-01)

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
by: Stéphane Bardet, et al.
Published: (2023-01-01)

IGF-1 influences Everolimus activity in medullary thyroid carcinoma
by: Erica eGentilin, et al.
Published: (2015-05-01)

A Calcitonin-Negative Neuroendocrine Tumor Derived from Follicular Lesions of the Thyroid
by: Ga Young Kim, et al.
Published: (2015-06-01)